🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ASGCT2024: Jamie Schafer highlights 5-locus multiplexing in T cells. Epigenetic editing’s unique multiplexibility may help streamline manufacturing and reduce genotoxic risk for highly engineered #CellTherapies. #ASGCT24 #EpigeneticEditing #Biotech

Chroma welcomes Jenny Marlowe, PhD, to #TeamChroma as Chief Development Officer. Jenny brings 15+ years of scientific and leadership experience in translational, preclinical development, and preclinical safety. bit.ly/3K82qsR #ClinicalDevelopment #EpigeneticEditing

Yesseinia Angleró-Rodríguez, PhD, will be heading to Milan for the EASLnews 2024 Congress to present new preclinical data highlighting efficient, specific, and durable silencing of #HBV using our #EpigeneticEditors. Read our abstract: bit.ly/3WSjkmN #EASLCongress

Ciao, Milano! Join us tomorrow at the EASLnews 2024 Congress, as Yesseinia Angleró-Rodríguez, PhD, shares new preclinical data showcasing the potential of our #EpigeneticEditing therapeutics to repress #HBV. Abstract: bit.ly/EASLCongress20… #EASLCongress

Today at #EASLCongress 2024, Yesseinia Angleró-Rodríguez, PhD, presented preclinical data supporting the potential of our #EpigeneticEditors to drive functional cure for #HBV via efficient, durable, and specific silencing. See the presentation here: chromamedicine.com/wp-content/upl…

Today we are excited to announce the expansion of our #EpigeneticEditing capabilities via an exclusive license agreement with Whitehead Institute to access CHARM, a novel technology developed in the lab of Chroma co-founder Jonathan Weissman. More: chromamedicine.com/2024/06/26/chr…

Check out this exciting new technology, CHARM, that we will leverage through an exclusive license with Whitehead Institute as we work to advance durable #EpigeneticEditing therapies to patients. 👇

Great update here by Jason Mast to the incredibly moving story of Sonia and Eric’s work in Jonathan Weissman's Lab. We are proud to be included in the article and have exclusively licensed CHARM. statnews.com/2024/06/27/pri…

Congratulations to @NoahGood on his well-deserved promotion to Chief Business Officer! Noah’s leadership and deep experience in life sciences #BusinessDevelopment have been instrumental to our growth, and we are proud to have him on #TeamChroma. #Biotech

Chroma welcomes Melissa J Moore, PhD, to our Board of Directors. Moore brings decades of experience directing RNA research and drug development at leading pharma companies and in academia. We are delighted to have her on #TeamChroma! Read more: chromamedicine.com/2024/07/18/chr…

Honoring #WorldHepatitisDay – Hepatitis is a major public health challenge impacting over 300M people. #HBV can cause severe liver disease + cancer. We are dedicated to advancing our #EpigeneticEditing technology to drive functional cure of HBV. worldhepatitisday.org

Thank you Labiotech.eu and Roohi Mariam Peter for showcasing our novel approach to #EpigeneticEditing including our recent partnership with the Whitehead Institute to exclusively license their #CHARM technology. Read more here: labiotech.eu/best-biotech/e… #Biotech

We are excited to share new data highlighting the potency of our #EpigeneticEditors targeting #PCSK9. Frederic Tremblay, PhD, will be presenting at the European Society of Cardiology 2024 Congress in London in September. For more information: esc365.escardio.org/ESC-Congress/s… #ESCCongress2024 #biotech

London calling! Yesterday at European Society of Cardiology Congress 2024, we shared preclinical data showcasing the best-in-class potency of our efficient + durable PCSK9-targeted #EpigeneticEditor. More: bit.ly/3XsBX0v #ESCCongress2024

We’re heading to the Windy City for the Hep B Foundation 2024 International HBV Meeting where we’ll share new preclinical data supporting CRMA-1001, our investigational #EpigeneticEditing drug for the treatment of chronic hepatitis B. More: hbvmeeting.org #HBV2024

We presented new preclinical data at the Hep B Foundation 2024 Int’l HBV Meeting demonstrating durable, dose-dependent suppression of hepatitis B surface antigen expression in vivo achieved with a single dose of CRMA-1001. Read more: chromamedicdev.wpengine.com/news/?tag=pres… #HBV2024 #Biotech

Nice piece about the data presented by Chroma Medicine colleague, X-less Yesse Angleró-Rodríguez, Hep B Foundation International #HBV meeting. Congrats to Yesse and the team on the amazing progress! liverdiseasenews.com/news/key-hbv-p…

Cheers to 3 years since launch! Celebrating the cutting-edge science, passionate team, and trusted investors fueling us as we work to shape the future of #GeneRegulation and revolutionize the treatment of disease with single-course #EpigeneticEditing therapeutics. Thank you team!

Join us at the 5th Annual Genome Editing Therapeutics Summit where Shane Wright M.S, MS, Scientist I, Platform Technologies, will discuss platform optimization through our PCSK9-EE, translation into an #HBV therapeutic (CRMA-1001) + more. genome-editing-therapeutics-summit.com #EpigeneticEditing

Celebrating a transformative milestone as the exceptional teams at Chroma Medicine + Nvelop Therapeutics unite to form nChroma Bio. Together, we are embarking on a shared mission to redefine the future of genetic medicines. Stay tuned for what’s next + follow: @nChromaBio.